Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN) (2020)
- Authors:
- Jamaspishvili, Tamara
- Patel, Palak G
- Niu, Yi
- Vidotto, Thiago
- Caven, Isabelle
- Livergant, Rachel
- Fu, Winnie
- Kawashima, Atsunari
- How, Nathan
- Okello, John B.
- Guedes, Liana B.
- Ouellet, Veronique
- Picanço, Clarissa
- Koti, Madhuri
- Reis, Rodolfo Borges dos
- Saad, Fred
- Mes-Masson, Anne-Marie
- Lotan, Tamara L
- Squire, Jeremy Andrew
- Peng, Yingwei P.
- Siemens, D. Robert
- Berman, David M.
- USP affiliated authors: REIS, RODOLFO BORGES DOS - FMRP ; SQUIRE, JEREMY ANDREW - FMRP
- Unidade: FMRP
- DOI: 10.1093/jnci/djaa032
- Subjects: PRÓSTATA; NEOPLASIAS; PROSTATECTOMIA; IMUNOHISTOQUÍMICA; ANÁLISE EM MICROSSÉRIES
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: JNCI: Journal of the National Cancer Institute
- ISSN: 0027-8874
- Volume/Número/Paginação/Ano: v. 112, n. 11, p. 1098-1104, 2020
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
JAMASPISHVILI, Tamara et al. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN). JNCI: Journal of the National Cancer Institute, v. 112, n. 11, p. 1098-1104, 2020Tradução . . Disponível em: https://doi.org/10.1093/jnci/djaa032. Acesso em: 15 fev. 2026. -
APA
Jamaspishvili, T., Patel, P. G., Niu, Y., Vidotto, T., Caven, I., Livergant, R., et al. (2020). Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN). JNCI: Journal of the National Cancer Institute, 112( 11), 1098-1104. doi:10.1093/jnci/djaa032 -
NLM
Jamaspishvili T, Patel PG, Niu Y, Vidotto T, Caven I, Livergant R, Fu W, Kawashima A, How N, Okello JB, Guedes LB, Ouellet V, Picanço C, Koti M, Reis RB dos, Saad F, Mes-Masson A-M, Lotan TL, Squire JA, Peng YP, Siemens DR, Berman DM. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN) [Internet]. JNCI: Journal of the National Cancer Institute. 2020 ; 112( 11): 1098-1104.[citado 2026 fev. 15 ] Available from: https://doi.org/10.1093/jnci/djaa032 -
Vancouver
Jamaspishvili T, Patel PG, Niu Y, Vidotto T, Caven I, Livergant R, Fu W, Kawashima A, How N, Okello JB, Guedes LB, Ouellet V, Picanço C, Koti M, Reis RB dos, Saad F, Mes-Masson A-M, Lotan TL, Squire JA, Peng YP, Siemens DR, Berman DM. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN) [Internet]. JNCI: Journal of the National Cancer Institute. 2020 ; 112( 11): 1098-1104.[citado 2026 fev. 15 ] Available from: https://doi.org/10.1093/jnci/djaa032 - Quantitative measurement of PTEN loss improves risk assessment in prostate cancer
- Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer
- Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment
- Emerging role of PTEN loss in evasion of the immune response to tumours
- TCGA analysis identifies distinct genomic features of oncogenic progression and outcome associated with hemizygous PTEN loss tumors
- Analysis of the impact of ZEB1 expression on pathway enrichment and immune cell abundance in prostate cancer
- A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer
- Extracellular vesicles: evolving factors in stem cell biology
- Quantitative assessment of PTEN loss (qPTEN) is strongly associated with biochemical recurrence and may improve treatment decisions after surgery
- In silico shows that PTEN loss and AR overexpression are associated with increased CD8+ T-cell and Treg density and earlier disease recurrence in prostate cancer
Informações sobre o DOI: 10.1093/jnci/djaa032 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003027463.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
